Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CMS reimbursement rulings, biologic classifications, and soft-tissue trial updates make Organogenesis Holdings Inc. filings anything but straightforward. If you have ever skimmed a 300-page 10-K trying to locate advanced wound-care revenue or verify how payer mix impacts margins, you know the challenge.
Stock Titan solves that problem. Our AI reads every Organogenesis annual report 10-K simplified, flags Medicare policy shifts in the latest Organogenesis 8-K material events explained, and generates plain-English takeaways. Need the Organogenesis quarterly earnings report 10-Q filing? It arrives seconds after EDGAR posts, complete with side-by-side trend analysis. Tracking management moves is just as easy: we deliver Organogenesis insider trading Form 4 transactions and Organogenesis Form 4 insider transactions real-time, so you can spot buying or selling patterns before they hit social feeds.
Every major form is covered: 10-K risk factors outline the regulatory path for Apligraf and Dermagraft; 10-Q disclosures quantify hospital adoption rates; 8-Ks highlight FDA clearances or DOJ subpoenas; the Organogenesis proxy statement executive compensation breaks down incentive plans tied to biologics revenue; and Organogenesis executive stock transactions Form 4 reveal insider sentiment. Our AI-powered summaries translate dense clinical language into business implications, letting you focus on decisions, not document mining.
Whether you鈥檙e a portfolio manager evaluating margin pressure or a sell-side analyst preparing an Organogenesis earnings report filing analysis, this page keeps you current. Start understanding Organogenesis SEC documents with AI鈥攏o more manual page flipping, just the insights that drive confident, timely calls.
Organogenesis Holdings Inc. (ORGO) 鈥� Schedule 13D/A (Amendment 10) filed 06/24/2025
The filing updates beneficial ownership information for a long-standing reporting group comprised of company founders, related trusts and affiliated investment vehicles. No purchase or sale prices are disclosed in the excerpt; however, the cover page states that the amendment was triggered by an event on June 24 2025.
Key ownership positions disclosed
- Alan A. Ades: 22,319,836 shares (17.6% of Class A common), of which 11.2 million are held with sole voting/dispositive power and 11.1 million with shared power.
- Albert Erani: 17,920,498 shares (14.1%) 鈥� approximately 6.8 million sole and 11.1 million shared.
- Glenn H. Nussdorf: 11,912,841 shares (9.4%) 鈥� 11.0 million sole, 0.9 million shared.
- Dennis Erani: 10,043,701 shares (7.9%) 鈥� 1.3 million sole, 8.7 million shared.
- Organo PFG LLC: 8,279,490 shares (6.5%) 鈥� all sole voting/dispositive.
- Other entities & individuals: Organo Investors LLC (2.9 million / 2.2%), Alan Ades 2014 GRAT (3.1 million / 2.4%) and Starr Wisdom (20,000 / <0.1%).
Based on the amounts reported, the group collectively controls approximately 76.4 million Class A shares. Although total shares outstanding are not provided in the excerpt, each of the first four individuals continues to exceed the 5% reporting threshold, indicating significant insider alignment with shareholders. The amendment does not specify whether positions increased or decreased relative to the prior filing.
No financial performance metrics, transaction prices or strategic commentary accompany the ownership data, suggesting that the filing is largely administrative鈥攗pdating share counts and voting arrangements among a pre-existing insider group.
Organogenesis Holdings Inc. (Nasdaq: ORGO) filed an 8-K covering the results of its 23 June 2025 Annual Meeting and a preferred-stock director election.
Board & Executive Matters
- Series A Convertible Preferred holders unanimously re-elected Garrett Lustig to the Board.
- All nine management-nominated directors were re-elected; the highest support was 72.4 million votes (95.8% of votes cast) for Gilberto Quintero, while the lowest was 68.9 million (93.9%) for Jon Giacomin.
- Say-on-Pay advisory resolution passed with 91.4% support (67.1 m for / 6.3 m against).
Capital Structure Proposal
- Shareholders approved鈥攂y 45.4 m for vs. 2.7 m against鈥攖he potential issuance of >20% of outstanding Class A shares upon conversion of Series A Preferred below Nasdaq 鈥渕inimum price,鈥� a step that could be deemed a change-of-control under Rules 5635(b)/(d).
Audit Matters
- RSM US LLP was ratified as independent auditor for FY 2025 with 96.4% support (103.6 m for / 3.9 m against).
Quorum: 107.5 million Class A votes were present (inclusive of 25.4 m as-converted preferred shares, subject to Nasdaq鈥檚 19.99% cap).
The filing is largely routine governance disclosure; however, the preferred-stock conversion approval introduces potential future dilution that current shareholders should monitor.
FAQ
What is the current stock price of Organogenesis Hldgs (ORGO)?
What is the market cap of Organogenesis Hldgs (ORGO)?
What is Organogenesis Holdings Inc?
Which markets does the company serve?
What types of products does Organogenesis offer?
How does Organogenesis ensure the quality of its products?
What is the core focus of Organogenesis in regenerative medicine?
How is Organogenesis positioned within the healthcare industry?
How does the company integrate clinical research into its product development?
